Roferon-A Articles

CHMP Update on current activities

10 July 2006

US pharma's R&D cost claims "cannot be reconciled with its IRS filings,"

5 December 2001

Roche hep C combo launched in Germany

29 June 2000

Mixed fortunes for companies from latest ODAC deliberations

21 September 1999

Roferon-A as adjuvant therapy for melanoma

10 August 1999

Roche posts strong first-half 1999 sales, driven by high uptake of Xenical

13 July 1999

New indication for Roferon-A approved in EU

24 June 1999

Gilead Sciences' revenues

10 February 1999

Xenical Recommended For Approval By CPMP

16 April 1998

Roche Sales Soar In 1st Quarter 1998

7 April 1998

Trend For 1997 Strong Sales Continues In USA

5 February 1998

Roche And Genentech In Marketing Deal

20 January 1997

US Quarterly Results Show Improvements

4 November 1996

Roche And Gilead In Hep C Copromotion

7 October 1996

Hoffman-La Roche's Roferon-A Cleared

30 October 1995

Roche Ahead Of Forecasts in 1995 First Half

4 September 1995

Roferon-A Recommendation

17 April 1995

Roche's Sales Ahead, Profit Growth Expected

23 January 1995

World Immunology, Rheumatology Markets

28 November 1994

CPMP Recommends Roferon-A Approval

7 November 1994

ROCHE RECORDS 11% INCREASE IN '93 SALES

17 January 1994

DRUGS FOR CANCER IMMUNOLOGY IN 1992

29 November 1993

ROCHE PHARMA HEALTHY IN 1st HALF

19 July 1993

ROCHE FORESEES GOOD OUTLOOK FOR 1993

3 May 1993

SALES "EXCELLENT" AT NIPPON ROCHE

22 March 1993

EXPANDING OPTIONS FOR HAIRY CELL LEUKEMIA

15 March 1993

PHARMACEUTICAL DESIGN: EPITOPE SELECTION

15 March 1993

ACCUTANE AND ROFERON A

2 November 1992

CANADA APPROVES INTERFERON ALFA

27 April 1992

ROFERON-A COULD SAVE SIGHT

16 March 1992

ROCHE SEES SALES INCREASE 19% IN 1991

20 January 1992

Showing 1-31 of 31 articles

Go to beginningPrevious
  • 1
NextGo to end